RNA Insider Trading Activity and SEC Form 4 Filings
RNA insider trading summary
Over the past 12 months, insiders at Avidity Biosciences, Inc. (RNA) reported 11 sales worth $2.5M by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $2.5M.
Latest RNA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 21, 2026 | W. Michael Flanagan | Chief Scientific Officer | Sell | $185K (2,558 @ $72.45) |
| Jan 21, 2026 | Arthur A Levin | Director | Sell | $127K (1,758 @ $72.45) |
| Jan 21, 2026 | Sarah Boyce | President and CEO | Sell | $579K (7,993 @ $72.45) |
| Jan 21, 2026 | Michael F MacLean | Chief Financial Officer | Sell | $198K (2,735 @ $72.45) |
| Jan 21, 2026 | W. Michael Flanagan | Chief Scientific Officer | Sell | $288K (3,976 @ $72.45) |
| Jan 21, 2026 | Michael F MacLean | Chief Financial Officer | Sell | $131K (1,807 @ $72.45) |
| Jan 21, 2026 | Teresa McCarthy | Chief Human Resources Officer | Sell | $105K (1,453 @ $72.45) |
| Jan 21, 2026 | Teresa McCarthy | Chief Human Resources Officer | Sell | $107K (1,476 @ $72.45) |
| Jan 21, 2026 | Sarah Boyce | President and CEO | Sell | $463K (6,394 @ $72.45) |
| Jan 21, 2026 | Steven George Hughes | Chief Medical Officer | Sell | $146K (2,017 @ $72.45) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.